We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/2/2021 08:06 | On and UP!!! Gla holders...a very exciting period for all concerned....news from SFX-01's Covid-19 Ards patient trial , coming soon...:-) | moneymunch | |
03/2/2021 07:53 | timbo- very nice one!! U have a great day!!! | pugugly | |
03/2/2021 07:50 | Then just like magic (after finnCapp have pocketed thir £700k for the fund raise) the finnCap analyst suddenly realises that there is value in the Covid/ARDs program and the Juvenescence partnership Perhaps Mark Brewer should give up his day job as an analyst and become a street magician instead | timbo003 | |
03/2/2021 07:44 | Analyst using rose tinted glasses again? | pugugly | |
03/2/2021 07:35 | New finnCap note out | timbo003 | |
03/2/2021 07:35 | Intuitive Investments Group plc (AIM: IIG) ("IIG"), a closed-end investment company focussed on the life sciences sector, announces an investment of £175,000 to acquire 2,187,500 million ordinary shares of Evgen Pharma plc (AIM:EVG) ("Evgen") at a price of 8 pence per share | euclid5 | |
02/2/2021 22:21 | Cheers bocker and AA, one thing for sure is the timing of the fundraise covers all eventualities of the fast approaching assessment by the DSMB of the first 100 patients recruited to the Covid patient trial....8p could look incredibly cheap if the trial gets the greenlight, along with positive detail from Huw...Bring it on!!! Gl :-) | moneymunch | |
02/2/2021 21:45 | >>Nobby I think most of us here could see this coming. On the positive side they have raised a decent amount, so there should be numerous value inflextion points before the market starts worrying where the next funding is coming from. The fact that it was heavily over subscribed suggests that if Finncap had wanted, they could have got a better price than 8p/share They have included an open offer in the fund raise, this is good news, but I suspect that at 8p/share the OO will be oversubscribed and there will not be many excess shares available. It is rather interesting that they have gone for a record date of Feb 10th for the OO. The norm is to have the record date either the same day as the announcement, or the day before the announcement, not 8 days after the funding announcement. This could help create demand for the shares leading up to February 10th, as new investors may be tempted to buy a few in order to apply for shares at 8p in the open offer. They talk about the OO shares being EIS qualifying. This will be irrelevant for nearly all existing shareholders (including myself). Even if the shares are deemed eligble for EIS tax breaks, the open offer participants will not be considered eligble EIS investors ☹️ϒ | timbo003 | |
02/2/2021 21:40 | Yep with you there Timbo. Looking good. Keep the posts flowing MM some great and informative research! | bocker01 | |
02/2/2021 21:27 | Worth commenting on the recruitment rate which seems to be going extremely well 🙂 As of yesterday they have recruited 89 patients onto the study, so they should get to 100 next week and hopefully these should have completed in the first or second week of March | timbo003 | |
02/2/2021 21:24 | 15/20% discount of current price at the time of placings. | albert arthur | |
02/2/2021 21:21 | >> timbo What's your view on the placing? We need some sensible comment around here.... | nobbygnome | |
02/2/2021 21:20 | >>>pugugly you forgot one: 2015 float at 37p 2017 placing at 12p 2019 placing at 15p Current placing at 8p | timbo003 | |
02/2/2021 21:18 | I remember me and you in TILS and 39p when nobody else was around... | albert arthur | |
02/2/2021 21:17 | I'm with you MM. | albert arthur | |
02/2/2021 19:44 | pugugly they're not allowed pens in prison | kingalf | |
02/2/2021 19:39 | MM - Could I take it that you failed maths at skool 2015 float at 37p 2017 placing at 12p Current placing at 8p PI's and II's well and truely shafted - - Repeat after me - 8p is less than 12p which is less than 37p Then write it out 100 times and you might understand some basic maths - | pugugly | |
02/2/2021 19:29 | Oooohhhh, showing your true colours at long last, and no doubt you're not going to like any good news on the recruitment and assessment of the first 100 patients coming soon. Gla :'-) Ps pug, whose been shafted, the share price is now back in double figures, and looks set for some serious upside imho...Evgen's prospects are up there with best, yet current market cap is ridiculously undervalued, and so the £11m raised plus £2m in the bank provides a springboard for great things and Transformational shareholder value imho...the market loves it...watch this space...On and Up!!!:-) | moneymunch | |
02/2/2021 19:17 | You make a good point pug. However the only way they can progress their indications is with a lot of cash. Their main crime is having the mission statement of doing everything by collaborative finding which has been proved to be a lie. Unfortunately a lot of investors believed it! | nobbygnome | |
02/2/2021 19:04 | And in the process provide an unrealistic expectation which then leads to disappointment when your nonsense inevitably doesn’t come to pass. It is a very serious point I am making! | nobbygnome | |
02/2/2021 19:02 | As I have said before I just hate misinformation and the problem is you produce bucket loads of it and then deny it! | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions